Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>OvaWatch mass monitoring completes OvaSuite portfolio.</li><li>With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass.</li><li>Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.</li></ul>

OvaWatch mass monitoring completes OvaSuite portfolio.With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass.Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.

Aspira Women's Health, Inc. - Water Tower Hour Recap

<ul><li>Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.</li><li>Dr. Milligan will report to CEO Nicole Sandford. She has more than 25 years of experience in the healthcare sector, with corporate experience that includes executive roles at biopharmaceutical companies Amgen, Genentech, Merck, and Organon.</li><li>Dr. Milligan supported pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health. </li></ul>

Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.Dr. Milligan will report to CEO Nicole Sandford. She has more than 25 years of experience in the healthcare sector, with corporate experience that includes executive roles at biopharmaceutical companies Amgen, Genentech, Merck, and Organon.Dr. Milligan supported pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health. 

Aspira Women's Health, Inc. - Aspira Women's Health Expands Senior Leadership Team

<ul><li>Aspira Women’s Health hosted an R&amp;D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.</li><li>CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD.</li><li>Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion.</li></ul>

Aspira Women’s Health hosted an R&amp;D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD.Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion.

Aspira Women's Health, Inc. - Aspira Women's Health Hosts R&D Day

<ul><li>Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October.</li><li>This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma.</li><li>Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis.</li></ul>

Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October.This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma.Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis.

Aspira Women's Health, Inc. - Provides Important Update on EndoCheck Diagnostic Test

<ul><li>Aspira Women’s Health made two reimbursement announcements this week.</li><li>On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1.</li><li>Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. </li></ul>

Aspira Women’s Health made two reimbursement announcements this week.On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1.Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. 

Aspira Women's Health, Inc. - Secures Important Reimbursements

United States

Calithera Biosciences, Inc. provides pharmaceutical products. The Company is focused on discovering and developing novel small molecule drugs against tumor metabolism and immunology for the treatment of cancer. Calithera Biosciences serves patrients in the United States.

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Minerva Neurosciences, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases. Minerva Neurosciences serves communities in the United States.

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company produces differentiated drugs that helps patients suffering from cancer, severe asthma, anemia, and other medical conditions. Pieris Pharmaceuticals serves customers worldwide.

KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company. The Company designs and develops proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. KALA BIO markets its products worldwide.

Calyxt, Inc. provides agricultural biotechnology services. The Company researches and develops seeds and food ingredients for agricultural, feed, and food applications, as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt markets its products in the United States.

Evelo Biosciences, Inc. operates as a bio-technology company. The Company develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases. Evelo Biosciences serves customers in the State of Massachusetts.

UNITY Biotechnology, Inc. operates as a biotechnology company. The Company develops therapeutics that prevents, halts, and reverses osteoarthritis, ophthalmology, and pulmonary diseases. UNITY Biotechnology serves the health care sectors in the United States.

vTv Therapeutics Inc. operates as a clinical-stage pharmaceutical company. The Company focuses on the discovery and development of human therapeutics to fill unmet medical needs. vTv Therapeutics serves customers in the United States.

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.

Biotron Limited specializes in the funding, management and commercialization of biomedical projects that result from research conducted at the John Curtin School of Medical Research, a research institute within the Australian National University.  The Group conducts diagnostic and therapeutic research with the intention of creating compounds and diagnostics that can be sold or licensed.

Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Alterity Therapeutics Limited operates as a biotechnology company. The Company researches and develops therapeutic drugs used for treatment of alzheimer's diseases and age related disorders. Alterity Therapeutics serves patients in Australia.

Daesung Microbiological Labs Co., Ltd. develops and manufactures canine, poultry, swine, and bovine drugs and vaccines.  The Company's products have applications for increasing immunity and preventing epidemic for livestock. Daesung Microbiological Labs also researches microorganism for ocean and soil improvement purposes.

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

D.Western Therapeutics Institute Inc. (4576 JP)

TRANS GENIC INC. develops, produces, and sells specific idiotype bearing antibody (bio reagent).  The Company also develops mutant mice and sells mice' genetic function analysis data.

Ribomic, Inc. develops ribonucleic acids (RNA) called aptamers. The company conduct research and develops new medication based on Ribomic Aptamer Refined Th erapeutics System. The company also conduct advisory to pharmaceutical companies and product licensing.

Prescient Therapeutics Limited is an oncology company. The Company researches, develop, and commercializes novel cancer treatments treatments. Prescient Therapeutics treats myeloma, breast, and pancreatic cancer.

Bharat Immunologicals & Biologicals Corporation Ltd. manufactures and distributes pharmaceutical drugs and vaccines. The Company's primary product is oral polio vaccine (OPV).

Vectorite Biotech Inc. is a biomedical company focused on the research and development of adult healthy cells and cell formulation, medical technologies and product development of targeted immune cell therapy treatment to treat disease and improve the patients' quality of life.

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aspira Women's Health (AWH US)

Aspira Women's Health, Inc. - Water Tower Hour Recap

The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.

Water Tower Research

Aspira Women's Health, Inc. - Aspira Women's Health Expands Senior Leadership Team

Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.

Water Tower Research

Aspira Women's Health, Inc. - Aspira Women's Health Hosts R&D Day

Aspira Women’s Health hosted an R&D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.

Water Tower Research

Aspira Women's Health, Inc. - Provides Important Update on EndoCheck Diagnostic Test

Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The...

Water Tower Research

Aspira Women's Health, Inc. - Secures Important Reimbursements

Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)